# Summary statistics - qualitative results

## EQA round: IFT2/26 - Immunophenotypisation

Deadline: 19.10.2026

Setup: groups - R (manufacturer of kit)

AV = assigned value
CVP = consensus of all participants
>>> ... expected result
> ... acceptable result
± ... result not assessed

$N_{tot}$ = total number of the results
$N_{rel}$ = relative number of the results

$N_{eva}$ = number of the results assessed
$N_{suc}$ = number of successful results
$S_{rel}$ = relative success

| Test / Sample / Group | AV | $N_{tot}$ | $N_{rel}$ [%] | Result | $N_{eva}$ | $N_{suc}$ | $S_{rel}$ [%] |
|---|---|---|---|---|---|---|---|
| (259) **HLA-B27** | | 60 | | | 60 | 60 | 100 |
| **Sample A** | | 60 | | | 60 | 60 | 100 |
| (12) Beckman Coulter | CVP >>> | 47 | 78 | Negative | | | |
| (36) Immunotech | CVP >>> | 2 | 3,3 | Negative | | | |
| (88) Becton Dickinson | CVP >>> | 8 | 13 | Negative | | | |
| (177) Mindray | CVP >>> | 3 | 5 | Negative | | | |
| **Sample B** | | 60 | | | 60 | 60 | 100 |
| (12) Beckman Coulter | CVP >>> | 47 | 78 | Positive | | | |
| (36) Immunotech | CVP >>> | 2 | 3,3 | Positive | | | |
| (88) Becton Dickinson | CVP >>> | 8 | 13 | Positive | | | |
| (177) Mindray | CVP >>> | 3 | 5 | Positive | | | |